Study identifies novel Parkinson's disease drug target

Jun 21, 2007

Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson’s disease and possibly for other degenerative neurological disorders.

In an upcoming issue of the journal Science, the investigators describe finding, in cellular and animal models, that blocking the action of an enzyme called SIRT2 can protect the neurons damaged in Parkinson’s disease from the toxic effects of alpha-synuclein, a protein that accumulates in the brains of Parkinson’s patients. The study, which also suggests that inhibiting this pathway could help in the treatment of other conditions in which abnormal proteins accumulate in the brain, is receiving early online release on the Science Express website.

“We have discovered a compelling new therapeutic approach for Parkinson’s disease, which we expect will allow our scientists – as well as those at pharmaceutical and biotech companies – to pursue innovative new drugs that will treat and perhaps even cure this disorder,” says Aleksey Kazantsev, PhD, director of MGH-MIND Drug Discovery Laboratory, who led the Science study. "Since the same sort of aggregation of misfolded proteins has been reported in
Huntington's and Alzheimer's diseases - as well as Lewy body dementia, which also involves alpha-synuclein deposits - we plan to test this approach in those
conditions as well."

Parkinson’s disease – characterized by tremors, rigidity, difficulty walking and other symptoms – is caused by the destruction of brain cells that produce the neurotransmitter dopamine. In recent years researchers at several centers have been studying the role of alpha-synuclein accumulations in dopamine-producing neurons, observed in patients with both inherited and sporadic Parkinson’s disease. MGH-MIND investigators have discovered that, in Parkinson’s, the alpha-synuclein molecule folds abnormally and form aggregates called inclusion bodies. Such inclusions of other abnormal proteins are seen in several disorders, but whether inclusions are toxic or protective to neurons has been controversial.

In a paper published last year in the Proceedings of the National Academy of Sciences, a research team led by Kazantsev analyzed ways to reduce the size of inclusions containing misfolded versions of alpha-synuclein or of the Huntington’s disease-associated protein huntingtin. They found that a compound called B2, which promotes the formation of larger inclusions, paradoxically appeared to reduce toxicity in cellular disease models, possibly by reducing the overall number of inclusions.

In the current study, the investigators began by seeking the mechanism underlying the observed effects of B2. Assays of the compound’s activity against a panel of key enzymes identified only one significant association – a weak but selective inhibition of SIRT2, which is known to regulate the cell cycle and may have a role in aging. An experiment using RNA interference to suppress SIRT2 and a related enzyme in human cell lines expressing alpha-synuclein confirmed that only the inhibition of SIRT2 reduced alpha-synuclein toxicity.

Kazantsev’s team then developed and identified more powerful inhibitors of SIRT2, based on the structure of B2. One of these novel inhibitors called AGK2 had 10 times the potency of B2 and was shown to protect dopamine-producing neurons from alpha-synuclein toxicity in cultured rat neurons and in an insect model of PD. Several additional compounds that act on the SIRT2 pathway have been identified, some which may be even better than AGK2 as candidates for drug development.

SIRT2 is known to act on a major protein component of microtubules, cellular structures that help move objects within cells, among other functions. The researchers theorize that inhibiting SIRT2 might promote microtubule-dependent transportation of alpha-synuclein into large aggregates; or it could strengthen microtubules that have been destabilized by misfolded alpha-synuclein.

Kazantsev explains, “For Parkinson’s disease, we can now pursue a straightforward drug development process by identifying potent and selective candidates from this class of compounds that can be tested in animal studies and eventual human trials. One of the most satisfying aspects is how this discovery validates our approach to drug discovery, which incorporates both the most advanced tools for screening candidate compounds and outstanding collaboration with our clinical and scientific experts in human disease.” Kazantsev is an assistant professor of Neurology at Harvard Medical School.

Source: Massachusetts General Hospital

Explore further: Longer needles recommended for epinephrine autoinjectors

add to favorites email to friend print save as pdf

Related Stories

Study shows troubling rise in use of animals in experiments

2 hours ago

Despite industry claims of reduced animal use as well as federal laws and policies aimed at reducing the use of animals, the number of animals used in leading U.S. laboratories increased a staggering 73 percent from 1997 ...

NY surveying banks on cyber security defenses

5 hours ago

(AP)—New York financial regulators are considering tougher cyber security requirements for banks to mandate more complex computer sign-ins and certifications from the contractors of their cyber defenses, the state's top ...

Life-saving train design is rarely used

5 hours ago

(AP)—Nearly a decade ago, the U.S. secretary of transportation stood at the site of a horrendous commuter train crash near downtown Los Angeles and called for the adoption of a new train car design that ...

Climate change may flatten famed surfing waves

6 hours ago

On a summer day in 1885, three Hawaiian princes surfed at the mouth of the San Lorenzo River on crudely constructed boards made from coastal redwoods, bringing the sport to the North American mainland.

Recommended for you

Quality control for adult stem cell treatment

1 hour ago

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected ...

A gene for brain size only found in humans

3 hours ago

About 99 percent of human genes are shared with chimpanzees. Only the small remainder sets us apart. However, we have one important difference: The brain of humans is three times as big as the chimpanzee ...

Experts warn of stem cell underuse

9 hours ago

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable ...

Longer needles recommended for epinephrine autoinjectors

21 hours ago

(HealthDay)—Given the increasing epidemic of obesity, epinephrine autoinjectors (EAIs) for anaphylaxis require longer needles to ensure intramuscular injection, according to a study published online Feb. ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.